{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:34:35Z","timestamp":1760920475220,"version":"build-2065373602"},"reference-count":39,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2023,5,14]],"date-time":"2023-05-14T00:00:00Z","timestamp":1684022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Separation Science"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>Cystic fibrosis is a life\u2010threatening genetic disease that causes damage to the lungs. Ivacaftor, the first drug to target the underlying defect of the disease caused by specific mutations, improves outcomes and reduces hospitalizations. In this study, quantitative determination of ivacaftor was performed by liquid chromatography, while high\u2010resolution mass spectrometric analyses were performed for qualitative determination. The validation studies of the developed methods were performed according to International Conference on Harmonisation Q2(R1) guideline. Ivacaftor was separated from its degradation product by using Phenomenex Kinetex C<jats:sub>18<\/jats:sub> (150 \u00d7 3\u00a0mm, 2.6\u00a0\u00b5m) column. The isocratic mobile phase for binary pump configuration was 0.1% (v\/v) formic acid in water and 0.1% (v\/v) formic acid in acetonitrile (27:63) (v\/v), pH\u00a0=\u00a02.5; the flow rate of 0.25\u00a0mL\/min was used in all methods. In the degradation studies, five degradation products were identified using high\u2010performance liquid chromatography ion trap time\u2010of\u2010flight mass spectrometric analyses: three of them have never been reported up to date; whereas the other two were existing in the literature and they were having Chemical Abstracts Services registry numbers since they were synthesized before for various other purposes. Also, analysis of an in\u2010lab prepared chemical equivalent of Kalydeco<jats:sup>\u00ae<\/jats:sup> and interlaboratory comparison were performed.<\/jats:p>","DOI":"10.1002\/jssc.202201061","type":"journal-article","created":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T13:49:00Z","timestamp":1683294540000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Determination of ivacaftor by liquid chromatography techniques in pharmaceutical formulation with interlaboratory comparison and characterization of five novel degradation products by high\u2010performance liquid chromatography ion trap time\u2010of\u2010flight mass spectrometry"],"prefix":"10.1002","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5492-0457","authenticated-orcid":false,"given":"Saniye","family":"\u00d6zcan","sequence":"first","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Pharmacy Anadolu University  Eskisehir Turkey"},{"name":"Central Analysis Laboratory, Faculty of Pharmacy Anadolu University  Eskisehir Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-518X","authenticated-orcid":false,"given":"Nafiz \u00d6nc\u00fc","family":"Can","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Pharmacy Anadolu University  Eskisehir Turkey"},{"name":"Central Analysis Laboratory, Faculty of Pharmacy Anadolu University  Eskisehir Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200505-840OE"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1238909"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-18.1.8"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0586"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0293-6"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.393637"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201798"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200393"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.0c00103"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.61427\/jcpr.v1.i2.2021.22","article-title":"Formulation, optimization and evaluation of gastroretentive alginate beads of ivacaftor by using factorial design","volume":"1","author":"Kalpana GB","year":"2021","journal-title":"J Clin Pharmaceut Res"},{"key":"e_1_2_10_13_1","article-title":"PBPK\u2010led guidance for cystic fibrosis patients taking elexacaftor\u2010tezacaftor\u2010ivacaftor with nirmatrelvir\u2010ritonavir for the treatment of COVID\u201019","author":"Hong E","year":"2022","journal-title":"medRxiv"},{"key":"e_1_2_10_14_1","first-page":"14","article-title":"Stability indicating RP\u2010HPLC method development and validation for the determination of ivacaftor in bulk and its pharmaceutical formulation","volume":"13","author":"Tanuja GIS","year":"2020","journal-title":"Int J Pharmaceut Res"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000829"},{"key":"e_1_2_10_16_1","article-title":"Optimized LC\u2010MS\/MS method for the high\u2010throughput analysis of clinical samples of Ivacaftor, its major metabolites, and lumacaftor in biological fluids of Cystic Fibrosis patients","author":"Schneider EK","year":"2017","journal-title":"JoVE"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2022.123518"},{"key":"e_1_2_10_18_1","first-page":"63","article-title":"Development and validation of Stability\u2010indicating RP\u2010UPLC Method for the Simultaneous Determination of Ivacaftor, Tezacaftor and Elexacaftor in bulk and their Formulation","volume":"12","author":"Lakshmi Maneka S","year":"2022","journal-title":"Res J Chem Environ"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2021.02.004"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2020.00373.X"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.13005\/ojc\/330354"},{"key":"e_1_2_10_22_1","first-page":"608","article-title":"Development and validation of a new and stability indicating RP\u2010HPLC method for the determination of Ivacaftor in presence of degradant products","volume":"5","author":"Chhabda PJ","year":"2013","journal-title":"Int J Pharm Pharm Sci"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.10.026"},{"key":"e_1_2_10_24_1","first-page":"45","article-title":"Simultaneous estimation of ivacaftor and tezacaftor in rat plasma by Liquid chromatography coupled with tandem\u2010mass\u2010spectrometry: Application to pharmacokinetic studies","author":"Sakuntala M","year":"2021","journal-title":"Thai J Pharm Sci"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmz120"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202200466"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202200088"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jssc.202201012"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573412916999200616125353"},{"key":"e_1_2_10_30_1","unstructured":"GuidelineIHT.Stability testing of new drug substances and products. Q1A (R2) Current Step.2003;4:1\u201324."},{"key":"e_1_2_10_31_1","unstructured":"GuidelineIHT.Validation of analytical procedures: text and methodology. Q2 (R1).2005;1:5."},{"key":"e_1_2_10_32_1","unstructured":"K\u00e1rp\u00e1tiRB PatyiG Basa\u2010D\u00e9nesO ORDASIBS AngiER GlavinasH et\u00a0al.Pharmaceutical combination composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives process for their preparation thereof and pharmaceutical compositions containing them.2017."},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-2614(69)80233-2"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chroma.2009.12.079"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5NP00073D"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jo000283d"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhet.5570310139"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3987\/R-1986-08-2321"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1139\/v65-202"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1139\/v62-351"}],"container-title":["Journal of Separation Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jssc.202201061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T11:53:06Z","timestamp":1760874786000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jssc.202201061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,14]]},"references-count":39,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/jssc.202201061"],"URL":"https:\/\/doi.org\/10.1002\/jssc.202201061","archive":["Portico"],"relation":{},"ISSN":["1615-9306","1615-9314"],"issn-type":[{"type":"print","value":"1615-9306"},{"type":"electronic","value":"1615-9314"}],"subject":[],"published":{"date-parts":[[2023,5,14]]},"assertion":[{"value":"2022-12-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2201061"}}